


Autolus

Nasdaq: AUTL



Second Quarter Financial Results and Operational Progress

August 6, 2020

Disclaimer

These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the “safe harbor” provisions of The Private Securities Litigation Reform Act of 1995, including statements about the Company's plans to develop and commercialize its product candidates, the Company's ongoing and planned clinical trials, including the timing and initiation of such trials and statements regarding whether or not such trials will be considered pivotal trials, the anticipated benefits of the Company's financial condition and results of operations, including its expected cash runway; the development of Autolus' product candidates, including statements regarding the timing of initiation, completion and the outcome of preclinical studies or clinical trials and related preparatory work, and the periods during which the results of the studies and trials will become available; Autolus' plans to research, develop, manufacture and commercialize its product candidates; the potential for Autolus' product candidates to be alternatives in the therapeutic areas investigated; and Autolus' manufacturing capabilities and strategy. All statements other than statements of historical fact contained in this presentation, including statements regarding the Company's future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward looking statements include the risks described in the “Risk Factors” section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 as amended, as well as those set forth from time to time in the Company's other SEC filings, available at www.sec.gov. The forward-looking statements contained in this presentation reflect the Company's views as of the date of this presentation regarding future events, except as required by law, and the Company does not assume any obligation to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this presentation.

Certain data in this presentation was obtained from various external sources. Such data speak only as of the date referenced in this presentation and neither the Company nor its affiliates, advisors or representatives make any representation as to the accuracy or completeness of that data or undertake to update such data after the date of this presentation. Such data involve risks and uncertainties and are subject to change based on various factors.

Agenda

1. Welcome and Introduction: Dr. Christian Itin, Chairman and CEO
2. Operational Highlights: Dr. Christian Itin
3. Financial Results and Overview: Andrew J. Oakley, CFO
4. Upcoming Milestones and Conclusion: Dr. Christian Itin
5. Q&A: Dr. Christian Itin and Andrew J. Oakley

Operational Highlights

Dr. Christian Itin
Chairman and CEO

Business update – second quarter 2020

Impact from COVID-19 on our programs has been limited to date

- In Q2 our lead programs AUTO1 and AUTO3 were not impacted significantly
 - AUTO1 pivotal study was initiated in Q2 as planned and potential impact of infection surges on timelines is being closely monitored
 - AUTO3 - continued to enrol patients in Q2 in unimpacted areas
 - Enrollment in the UK and NYC area was paused
 - Enrollment continued in other parts of the US
 - Infection surges are being closely monitored to ensure continued enrollment
- Impact on AUTO4 Ph1 clinical trial
 - Study is being conducted in the UK and Spain
 - Healthcare systems in both countries heavily impacted, leading to a pause of enrolment in Q2
 - Expect first data in H1 2021 (from Q4 2020)
- Preclinical programs have been minimally impacted
 - Expect AUTO5, AUTO6NG, AUTO7 to enter clinical development in 2021
 - AUTO1NG in pALL and AUTO8 in multiple myeloma are on track to start Ph1 in H2 2020

Corporate highlights – second quarter 2020

Advancing our clinical programs to value inflection; positive updates at ASCO & EHA

- AUTO1 in adult ALL;
 - AUTO1 Ph1 data at EHA continues to show favorable safety profile and high level of clinical activity
 - AUTO1 pivotal program initiated and enrolling
 - On track for full data by end 2021
- AUTO3 in DLBCL
 - AUTO3 data at ASCO continue to show encouraging clinical activity alongside tolerable safety
 - Recommended Phase 2 dose range of 150 - 450 x 10⁶ cells with pembrolizumab preconditioning
 - Next data update at ESMO Sept 18, 2020
 - Outpatient cohort initiated, data update Q4 2020
- Additional clinical data expected at ESMO and ASH through September and December 2020
 - AUTO1 in adult ALL, plan to present longer term follow up data (likely ASH)
 - AUTO3 in DLBCL, updated data and longer term follow up from ALEXANDER study (ESMO and likely ASH)
 - Analyst call planned post ESMO

Corporate highlights – second quarter 2020

Advancing next generation preclinical programs to value inflection; positive updates at AACR

- AUTO5 in TRBC2+ T-cell lymphomas
 - Currently no T cell therapy approved for T cell lymphoma
 - Autolus' TRBC1 programmed T cell product candidate, AUTO4, progressing in clinical study
 - Preclinical data demonstrated highly selective targeting of TRBC2 by novel CAR T candidate, AUTO5
- AUTO6NG in SCLC
 - Preclinical data suggested broader application beyond neuroblastoma with demonstrated efficacy in an *in vitro* SCLC model
- AUTO7 in Prostate Cancer
 - Preclinical data highlighted activity in an immunologically cold tumor using proprietary Autolus modular programming technology
- AUTO5, AUTO6NG & AUTO7 next generation preclinical programs to enter Ph1 in 2021

Operational highlights – second quarter 2020

Board and Management Team evolution, plus manufacturing flexibility extended

- Dr Jay T Backstrom appointed to Board of Directors
 - Dr Backstrom currently serves as EVP, Head of Research & Development at Acceleron Pharma Inc
 - Prior to Acceleron, Dr Backstrom served as CMO and Head of Regulatory Affairs at Celgene Corporation
 - Dr Backstrom oversaw development of Celgene’s substantial hemato-oncology pipeline including its CAR T programs
- Dr Nushmia Khokhar promoted to Senior Vice President, Clinical Development
 - Dr Khokhar will take over the clinical leadership role at Autolus
 - Dr Khokhar is a board-certified oncologist and has led several successful registration trials within the industry including the global daratumumab program at Janssen Oncology
 - Dr Vijay Peddareddigari, Chief Medical Officer, will be leaving the Company
- Extended manufacturing capacity at the Cell and Gene Therapy Catapult to secure initial commercial launch capability

No approved CAR T therapy for adult ALL patients

Successful therapy requires high level of activity and long persistence paired with good tolerability

ALL is a significant opportunity:

Up to

8,400*

new cases of adult ALL diagnosed yearly worldwide

Projected patients in US & EU

3,000

addressable patient population

High unmet medical need

- Combination chemotherapy enables 90% of adult ALL patients to experience CR, but only 30% to 40% will achieve long-term remission
- Median overall survival is < 1 year in r/r ALL
- Only approved redirected T cell therapy approved for adults generally is blinatumomab
- CAR T therapies are highly active, but no clear sense of durability without subsequent allograft
- Patients are generally more fragile, more co-morbidities, yet CAR T toxicities in this setting have been notable with high incidences of severe CRS and cases of fatal neurotoxicity

FDA granted AUTO1 orphan drug designation for ALL

AUTO1 potentially has a superior efficacy profile compared to standard of care

Comparable and manageable safety profile

	¹ AUTO1		Standard of Care	
	All patients	Closed Process	² Blinatumumab	³ Inotuzumab
Patient Numbers	19	13	271	218
CR Rate	84%	92%	44%	80.7%
EFS 6m	62%	76%	31%	mPFS 5m
CRS ≥ Grade 3	0%	0%	3%	0%
Neurotox ≥ Grade 3	16%*	15%*	13%	0%
Other notable toxicities				14% Hepatic VoD

- Approximately 50% of blinatumumab and inotuzumab patients received subsequent HSCT
- Veno-Occlusive Disease (VoD) during treatment and following subsequent HSCT, with the latter causing a higher post-HSCT non-relapse mortality rate, has limited inotuzumab uptake

AUTO1 is the first Autolus program to move into a pivotal study

Preliminary Ph1 data supports development as a stand-alone therapy

Pivotal study, AUTO1-AL1, in adult ALL:



CTA approved by the MHRA in January 2020 and US IND accepted by the FDA in April 2020



Ph1b run-in component, prior to single arm Ph2 pivotal study



100 relapsed / refractory adult ALL patients



Primary endpoint: overall complete response rate (CR/CRi)



Secondary endpoints: include MRD-negative CR EFS and DoR

Current status of CAR T Cell therapies in DLBCL


Two approved products (Yescarta[®] and Kymriah[®]) and one near to approval (liso-cel)

Efficacy

- Despite high ORR (70-80%) and high best CRR (40-55%), only 29-37% patients achieve durable CRR in DLBCL^{1,2}
- Approximately a third of CRs are lost over time
- Loss of CRs are caused by PD-L1 upregulation³ which contributes to CAR T exhaustion and CD19 antigen loss⁴


Safety

- High rates of severe cytokine release syndrome (13-22%) and severe neurotoxicity (12-28%)^{2,4}
- Early onset and severity of toxicities requires intensive inpatient management



Encouraging signs of durable complete responses


10 of 11 complete responses ongoing



At $\geq 150 \times 10^6$ dose, all complete responses are ongoing with a median follow up 3 months (range 1-12m)

AUTO3 is designed to reach total addressable r/r DLBCL population

AUTO3 has the potential to be a true outpatient therapy



Approved CD19 CAR T Products

- Patients receive approved products as inpatients in CoEs because of the high rate and severity of toxicities and the need for intensive patient management
Market opportunity limited to ~20% of patients

AUTO3

- Minimal toxicity management of AUTO3 should allow treatment across all settings of care
- AUTO3 grows the addressable market and maximizes reimbursement options compared to approved products
- >80% of 3L+ and 2L DLBCL patients are treated outside of academic CoEs

AUTO3 is designed for potential best-in-class efficacy and safety

Differentiated product profile should open access to full market opportunity



First-in-class CD19 & CD22 CAR with novel signaling domains, design & manufacturing process



Designed to provide best-in-class efficacy with high rates of durable complete responses



Potential for best-in-class safety with no need for intensive patient management



Highly differentiated clinical profile with potential for true outpatient treatment across all settings of care









Outpatient cohort initiated with potential to move to a pivotal study early 2021



AUTO3 has the potential to reach patients without the need for referrals to academic centers

Broad pipeline of next generation programs

Designed to address limitations of current T cell therapies

PRODUCT	INDICATION	TARGET	PRECLINICAL	PHASE 1
AUTO1NG	ALL	CD19 & CD22		H2 2020
AUTO3NG	DLBCL	CD19 & CD22		Life cycle mgmt
AUTO5	TRBC2+ Peripheral TCL	TRBC2		2021
AUTO6NG	Neuroblastoma; Melanoma; Osteosarcoma; SCLC	GD2		2021
AUTO7	Prostate Cancer	PSMA		2021
AUTO8	Multiple Myeloma	BCMA & CAR X		H2 2020

 B Cell Malignancies
  T Cell Lymphoma
  GD2+ Tumors
  Prostate Cancer
  Multiple Myeloma

Financial Results

Andrew J. Oakley
CFO

Financial summary

USD m	2Q 2019	2Q 2020	Variance
Grant Income	0.3	0.3	(0.0)
R&D	(26.2)	(31.3)	(5.1)
G&A	(11.4)	(8.5)	2.9
Total Op Expenses, net.	(37.2)	(39.5)	(2.3)
Interest Income	1.1	(0.0)	(1.1)
Other Income	4.4	0.5	(3.9)
Tax Benefit	3.3	7.0	3.7
Net Loss	(28.5)	(32.0)	(3.5)

USD m	Mar 31 2020	Jun 30 2020	Variance
Cash Balance	243.3	212.0	(31.3)

Cash runway into 2022

*Variances due to rounding

Upcoming Milestones and Conclusions

Dr. Christian Itin
Chairman and CEO

Multiple clinical data points expected through H2 2020 / 2021

Product	Indication	Target	Event
B Cell Malignancies			
AUTO1	Adult ALL	CD19	<ul style="list-style-type: none"> • Ph1 long-term follow up Q4 2020 • Pivotal data end of 2021
AUTO1NG	Pediatric ALL	CD19 & 22	<ul style="list-style-type: none"> • Start Ph1 H2 2020
AUTO3	DLBCL	CD19 & 22	<ul style="list-style-type: none"> • Ph1 data update H2 2020 (ESMO and likely ASH)
Multiple Myeloma			
AUTO8	Multiple Myeloma	BCMA & CAR X	<ul style="list-style-type: none"> • Start Ph1 study H2 2020
T Cell Lymphoma			
AUTO4	TRBC1+ Peripheral TCL	TRBC1	<ul style="list-style-type: none"> • Ph1 interim data H1 2021
Solid Tumors			
AUTO6NG	Neuroblastoma; Melanoma; Osteosarcoma; SCLC	GD2	<ul style="list-style-type: none"> • Start Ph1 2021
AUTO7	Prostate Cancer	PSMA	<ul style="list-style-type: none"> • Start Ph1 2021
Allogeneic Approach			
Undisclosed	Undisclosed	Undisclosed	<ul style="list-style-type: none"> • Start Ph1 Q4 2020

Autolus poised for value inflection in 2020

- AUTO1/AUTO1NG
 - Currently enrolling Autolus' first Ph1b / 2 pivotal program in adult ALL
 - Granted orphan drug designation by the FDA for treatment of ALL
 - Pediatric ALL – moving forward with AUTO1NG
- AUTO3
 - Outpatient treatment cohort started in Q2 2020
 - Next data update planned at ESMO 2020
 - Pivotal study could start early 2021
- Key data releases expected at upcoming medical conferences, e.g. ESMO, ASH
- Cash on hand \$212m as at June 30, 2020

Q&A

Dr. Christian Itin and Andrew Oakley



Thank you